The Bottom Line
Medicare’s GLP-1 Bridge offers certain weight-management drugs to qualifying Part D beneficiaries from July 1, 2026, through December 31, 2027. Eligible participants pay a $50 copay, but that payment does not count toward the Part D deductible or true out-of-pocket costs. Access requires an eligible plan, a qualifying prescription, specified clinical criteria and prior authorization.
A new Medicare demonstration can expand access to selected GLP-1 drugs for some beneficiaries who use them to reduce excess body weight and maintain weight reduction. The Medicare GLP-1 Bridge operates outside the normal Part D payment flow, which makes its rules different from ordinary plan coverage.
The program is not automatic and not open to every person with Medicare. CMS says the Bridge applies only to beneficiaries enrolled in eligible Part D plan types who meet clinical criteria and receive prior authorization. Before changing or filling a prescription, beneficiaries should work with their prescriber, plan and pharmacy.
Who can qualify
Applicants must be adults using the requested drug for weight management together with ongoing lifestyle modification, including structured nutrition and physical activity consistent with the FDA-approved label. A prescriber must attest that the patient met one of the following thresholds when GLP-1 therapy began:
| BMI at therapy start | Additional condition |
|---|---|
| 35 or higher | No additional listed condition required |
| 30 or higher | Heart failure with preserved ejection fraction, uncontrolled hypertension despite two medications, or chronic kidney disease stage 3a or above |
| 27 or higher | Prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease |
Eligible plan types include standalone prescription drug plans and certain Medicare Advantage coordinated-care plans with drug coverage, including HMOs, HMO point-of-service plans, and local or regional PPOs. Plan type is only one part of eligibility; clinical criteria and the purpose of the prescription also matter.
Which drugs are included
CMS currently lists Foundayo, Wegovy injections and tablets, and the Zepbound KwikPen when used to reduce excess body weight and maintain weight reduction. Availability and formulations can change, so beneficiaries should verify the current official list before relying on a specific product.
The Bridge is designed for weight-management use. CMS says type 2 diabetes, moderate-to-severe obstructive sleep apnea and noncirrhotic metabolic dysfunction-associated steatohepatitis are indications eligible for ordinary Part D coverage. A beneficiary prescribed a GLP-1 for one of those covered indications should continue to obtain it through the Part D plan rather than the Bridge.
What the $50 copay does—and does not do
Eligible beneficiaries pay $50 for a drug furnished through the Bridge. Because the demonstration operates outside the Part D benefit payment and coverage flow, the Part D deductible does not apply. The $50 also does not count toward TrOOP, the spending measure used to track progress through the Part D benefit.
CMS further states that the low-income subsidy does not reduce the Bridge copay. That is an important distinction for Extra Help beneficiaries who may be accustomed to lower cost sharing under Part D. The $50 figure should not be interpreted as the total cost of all related care; office visits, laboratory work, supplies or treatment for side effects may follow separate coverage rules.
A five-step eligibility check
- Confirm that you are enrolled in a qualifying Part D or Medicare Advantage drug plan.
- Ask whether the prescription is for weight management or an indication already covered by Part D.
- Review the BMI and medical-condition criteria with the prescriber.
- Have the prescriber submit the official prior-authorization request.
- Confirm approval, the participating pharmacy and expected $50 copay before pickup.
Three points that can prevent coverage confusion
1. The Bridge is separate from normal Part D processing
In 2026, CMS uses a central processor for prior authorization, claims adjudication and pharmacy payment. Part D sponsors do not need to opt in for an eligible beneficiary to access the Bridge, but the beneficiary still needs an eligible plan type.
2. Prior authorization is essential
A prescription alone does not establish eligibility. The provider must complete the authorization process and attest to the clinical criteria. Beneficiaries should not assume an ordinary plan denial automatically creates Bridge coverage.
3. Do not switch treatment without medical guidance
GLP-1 drugs have dosing, contraindication and side-effect considerations. Coverage information is not a treatment recommendation. A prescriber should determine whether a product is medically appropriate and how any transition should be handled.
Where beneficiaries can get help
CMS directs beneficiaries to Medicare.gov/glp1bridge to review the program and check whether they might qualify. Questions can also be directed to 1-800-MEDICARE (1-800-633-4227); TTY users can call 1-877-486-2048.
Before calling, gather the Medicare card, current plan name, medication list and prescriber information. Do not email personal medical or identifying information to a general mailbox. CMS specifically warns that technical inquiries sent to the program mailbox should not include protected health information.
Questions to ask before the first fill
Ask the prescriber which eligibility pathway applies and whether the medical record documents the BMI and qualifying condition at the correct point in time. Ask the pharmacy whether it can process Bridge claims and whether the authorization is visible before traveling to pick up the drug. Also confirm which formulation and dose are approved; coverage of a product name does not automatically mean every presentation is included.
Because the Bridge copay does not count toward TrOOP, beneficiaries should keep its receipts separate from ordinary Part D spending records. If another indication may qualify under normal Part D, ask the plan and prescriber which path applies before submitting a Bridge request. The correct route affects cost sharing, authorization and how spending is tracked.
What to Watch
- Updates to the list of eligible drugs or formulations.
- Changes to provider, pharmacy or prior-authorization instructions.
- How the program transitions when the demonstration ends December 31, 2027.
- Annual Part D plan changes that may affect ordinary coverage for other indications.
- Any new CMS beneficiary guidance on appeals or pharmacy access.
Sources and Methodology
This article uses CMS beneficiary and provider guidance last modified in July and August 2026. It summarizes program administration and does not provide medical advice or determine individual eligibility.
- CMS: Medicare GLP-1 Bridge overview
- CMS: provider eligibility and clinical criteria
- CMS: prior-authorization form
- Medicare.gov: beneficiary information
Read Also
Latest News | Podcasts
Health information notice: Coverage rules do not replace medical advice. Discuss treatment, risks and dosing with a licensed clinician.
